| Literature DB >> 32779267 |
Dag Sehlin1, Pawel Stocki2,3, Tobias Gustavsson1, Greta Hultqvist4, Frank S Walsh2,3, J Lynn Rutkowski2,3, Stina Syvänen1.
Abstract
Transferrin receptor 1 (TfR1) mediated transcytosis is an attractive strategy to enhance brain uptake of protein drugs, but translation remains a challenge. Here, a single domain shark antibody VNAR fragment (TXB2) with similar affinity to murine and human TfR1 was used to shuttle protein cargo into the brain. TXB2 was fused to a human IgG1 Fc domain (hFc) or to the amyloid-β (Aβ) antibody bapineuzumab (Bapi). TXB2-hFc displayed 20-fold higher brain concentrations compared with a control VNAR-hFc at 18 hours post-injection in wt mice. At the same time point, brain concentrations of Bapi-TXB2 was threefold higher than Bapi. In transgenic mice overexpressing human Aβ, the brain-to-blood concentration ratio increased with time due to interaction with intracerebral Aβ deposits. The relatively stable threefold difference between Bapi-TXB2 and Bapi was observed for up to 6 days after injection. PET imaging and ex vivo autoradiography revealed more parenchymal distribution of Bapi-TXB2 compared with Bapi. In conclusion, the TXB2 VNAR shuttle markedly increased brain uptake of protein cargo and increased brain concentrations of the Aβ binding antibody Bapi.Entities:
Keywords: Alzheimer's disease (AD); amyloid-β (Aβ); antibody; blood-brain barrier (BBB); positron emission tomography (PET); receptor mediated transcytosis
Year: 2020 PMID: 32779267 DOI: 10.1096/fj.202000610RR
Source DB: PubMed Journal: FASEB J ISSN: 0892-6638 Impact factor: 5.191